Phase 4 Completed N=102 Randomized Diagnostic

Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm

Atrial Fibrillation · Chronic Obstructive Pulmonary Disease · Deep Vein Thrombosis

Source: ClinicalTrials.gov NCT00511173 ↗

Enrolled (actual)

102

Serious AEs

0.0%

Results posted

Dec 2012

Primary outcomePrimary: In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk). — 46.9; 35.4 mg/wk — p=< 0.05

Summary

This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.

Outcome Measures

Outcome	Result	p-value
PRIMARY In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk).	46.9; 35.4	< 0.05 sig

Eligibility Criteria

Inclusion Criteria

Diagnosed patients with atrial fibrillation, deep venous thrombosis, or pulmonary embolism requiring warfarin therapy

Exclusion Criteria

Patients with atrial fibrillation, deep venous thrombosis, or pullmonary embolism requiring warfarin therapy who do not consent to participate

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00511173). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.